Vera Therapeutics, Inc. Class A Share Price
VERAVera Therapeutics, Inc. Class A Stock Performance
Open $46.99 | Prev. Close $46.07 | Circuit Range N/A |
Day Range $45.52 - $47.55 | Year Range $18.53 - $56.01 | Volume 51,532 |
Average Traded $46.16 |
Vera Therapeutics, Inc. Class A Share Price Chart
About Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Jan-26 | $46.99 | $46.19 | +0.00% |
06-Jan-26 | $46.99 | $46.19 | -5.00% |
02-Jan-26 | $50.74 | $48.62 | -3.93% |
31-Dec-25 | $50.60 | $50.61 | -1.03% |
30-Dec-25 | $51.42 | $51.13 | -2.06% |
29-Dec-25 | $53.26 | $52.21 | -2.56% |
26-Dec-25 | $55.28 | $53.58 | -3.81% |
FAQs on Vera Therapeutics, Inc. Class A Share Price
Can I buy Vera Therapeutics, Inc. Class A shares in India?
What is the share price of Vera Therapeutics, Inc. Class A?
What is the 5 year returns of Vera Therapeutics, Inc. Class A?
What are the high & low stock price of Vera Therapeutics, Inc. Class A today?
What is the 52-week high and low of Vera Therapeutics, Inc. Class A stock?